AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.009

0.000

Volume:7.63M

Turnover:68.68K

Market Cap:39.04M

PE:-0.50

High:0.009

Open:0.009

Low:0.009

Close:0.009

52wk High:0.040

52wk Low:0.009

Shares:4.34B

Float Shares:3.34B

Volume Ratio:2.66

T/O Rate:0.23%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-174.71%

ROA:-44.61%

PB:1.58

PE(LYR):-0.50

Loading ...

Overview Company News Filings

Radiopharm Theranostics director Paul Hopper files initial beneficial ownership statement

Regis Healthcare to Benefit from Higher Govt Spending on Aged Care, Says Jefferies

MT Newswires Live

Radiopharm Theranostics files Form 3 for CFO Aaron James Laurita

Radiopharm Theranostics Ltd-Financial Services and Company Secretary Changes

THOMSON REUTERS

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

MT Newswires Live

Radiopharm starts first-in-human Phase 1 trial of RAD 402 in advanced prostate cancer

Radiopharm Theranostics Reports Decline in Cash at End of March

MT Newswires Live

Radiopharm Says In-Human Trial Results Show 'Meaningful' Tumor Uptake, Favorable Safety Profile for Radiotherapeutic Candidate

MT Newswires Live

Radiopharm Theranostics Ltd-Rad Initial Findings From Phase 1 177Lu-Rad202 Trial

THOMSON REUTERS

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2B Imaging Trial of Rad 101 for Diagnosis of Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics Completes Dosing of Final Patient in Phase 2B Imaging Trial in Recurrent Brain Metastases from Solid Tumors

MT Newswires Live

BRIEF-Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-Rad202 Phase 1 Dose Escalating Clinical Trial

THOMSON REUTERS

Radiopharm Theranostics Ltd: on Track to Complete Phase 1 Dose Escalation by End of 2026

THOMSON REUTERS

Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%

MT Newswires Live

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for Rad101 in the U.S.

THOMSON REUTERS

BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101

Radiopharm Theranostics Ltd - Rad and Siemens Sign Clinical Supply Agreement for Rad101

THOMSON REUTERS

Radiopharm Theranostics director Noel Donnelly files initial beneficial ownership statement

Radiopharm Theranostics files Form 3 for director Denise Hester Larkin

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/RAD.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.009,"timestamp":1789020720000,"preClose":0.009,"halted":0,"volume":7630853,"delay":0,"changeRate":0,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.0179,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-10 16:12:00 AEST","open":0.009,"high":0.009,"low":0.009,"amount":68678,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0179,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.009,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":2.659653749847878,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.009,"auctionPrice":0.009,"auctionVolume":3561867,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020476198}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-44.61%","roe":"-174.71%","lyrEps":-0.0179,"volumeRatio":2.659653749847878,"shares":4337549000,"dividePrice":0,"high":0.009,"amplitude":0,"preClose":0.009,"low":0.009,"week52Low":0.009,"pbRate":"1.58","psRate":"2.89","week52High":0.04,"institutionHeld":0,"latestPrice":0.009,"eps":-0.0179,"divideRate":0,"volume":7630853,"delay":0,"ttmEps":-0.0179,"open":0.009,"prevYearClose":0.025,"prevWeekClose":0.009,"prevMonthClose":0.01,"prevQuarterClose":0.019,"fiveDayClose":0.01,"twentyDayClose":0.012,"sixtyDayClose":0.02,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633674186","title":"Radiopharm Theranostics director Paul Hopper files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633674186","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633674186?lang=en_us&edition=fundamental","pubTime":"2026-05-06 18:09","pubTimestamp":1778062182,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Paul Hopper reported 53.9 million ordinary shares held directly, with additional indirect holdings of 93.57 million shares via Kilinwata Investments Pty Ltd and 250,000 shares held by his spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL4NKFwh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633708962","title":"Regis Healthcare to Benefit from Higher Govt Spending on Aged Care, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2633708962","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633708962?lang=en_us&edition=fundamental","pubTime":"2026-05-05 07:14","pubTimestamp":1777936479,"startTime":"0","endTime":"0","summary":"Regis Healthcare  is expected to reap benefits from higher government funding into aged care sector, Jefferies said Monday in a note, adding that it is awaiting clarity from the upcoming federal budget announcement this month.The government has announced plans for a AU$3 billion investment in aged care, which includes an increased accommodation supplement.The investment firm assumes that if 40% of Regis' residents received a AU$15 higher daily accommodation supplement, the company could see around a 10% boost in EBITDA per place over 12 months. Regis expects fiscal 2026 underlying EBITDA of around AU$135 million.Jefferies is also confident in the company's fiscal 2027 outlook despite near-full occupancy as Regis continues to expand its portfolio and increase the proportion of residents paying Refundable Accommodation Deposit . The company reported average occupancy of 95.9% in mature homes in the third quarter.Jefferies maintained a buy rating and increased its price target by 35% to A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7113","BK4128","BK7067","HCSG","BK4137","XBI","RGS","LU0128526141.USD","BK4192","LABU","RAD","LU0029874061.USD","REG.AU","RAD.AU","BK4588","BK4581","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669690","title":"Radiopharm Theranostics files Form 3 for CFO Aaron James Laurita","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669690","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669690?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:52","pubTimestamp":1777600337,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics CFO Aaron James Laurita reported 26,357 ordinary shares in an initial Form 3 filing dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDLc8XzQv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632369800","title":"Radiopharm Theranostics Ltd-Financial Services and Company Secretary Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2632369800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632369800?lang=en_us&edition=fundamental","pubTime":"2026-05-01 07:53","pubTimestamp":1777593207,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUEBFV78N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631757805","title":"Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631757805","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631757805?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:11","pubTimestamp":1777507899,"startTime":"0","endTime":"0","summary":"Regis Healthcare  said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization  of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit  cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4137","BK4588","BK7113","RAD.AU","XLV","LABU","RGS","BK7067","LU0029874061.USD","BK4192","REG.AU","LU0128526141.USD","BK4128","BK4585","HCSG","RAD","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629298833","title":"Radiopharm starts first-in-human Phase 1 trial of RAD 402 in advanced prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629298833","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629298833?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:12","pubTimestamp":1776942752,"startTime":"0","endTime":"0","summary":"Radiopharm completed enrollment in Phase 2b imaging trial of 18F-RAD101 in recurrent brain metastases, building on interim results already presented that supported performance versus MRI.Management flagged that confirmation of these findings would trigger preparation for a multi-center, multi-country Phase 3 registrational study.Initial Phase 0/1 data for 177Lu-RAD202 were presented at AACR 2026, showing encouraging tumor targeting with tolerability that supported further dose escalation.Radiopharm initiated two first-in-human studies, dosing first patients in Lu177-RV-01 across various tumor types and Tb161-RAD402 in advanced prostate cancer.Company guided to additional RAD202 and RAD204 dose-cohort readouts in mid-2026, setting up near-term clinical catalysts for pipeline valuation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL8vzXqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","BK7067","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","IE00BKPKM429.USD","BK4112","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","IE00B64PRP62.GBP","RAD.AU","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629605001","title":"Radiopharm Theranostics Reports Decline in Cash at End of March","url":"https://stock-news.laohu8.com/highlight/detail?id=2629605001","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629605001?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:18","pubTimestamp":1776921523,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) said it closed the March quarter with a cash position of AU$19.2 million, down from AU$34.5 million at the end of the previous quarter, according to a Thursday filing","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628157977","title":"Radiopharm Says In-Human Trial Results Show 'Meaningful' Tumor Uptake, Favorable Safety Profile for Radiotherapeutic Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2628157977","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628157977?lang=en_us&edition=fundamental","pubTime":"2026-04-20 12:05","pubTimestamp":1776657931,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  said the first in-human findings from the ongoing Phase 0/1 HEAT trial evaluating its radiotherapeutic candidate, lutetium-177-RAD202, showed \"meaningful\" tumor uptake and a favorable safety profile at the lowest dose level of 30 millicurie , according to a Monday Australian bourse filing.Organ-level absorbed radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation, while no dose-limiting toxicities or treatment discontinuations due to adverse events were observed, per the filing.The radiotherapeutic candidate was generally well tolerated in the first three treated patients, with predominantly grade one to two treatment-emergent adverse events, the filing added.Radiopharm Theranostics' shares rose past 2% in recent trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628799033","title":"Radiopharm Theranostics Ltd-Rad Initial Findings From Phase 1 177Lu-Rad202 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628799033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628799033?lang=en_us&edition=fundamental","pubTime":"2026-04-20 06:54","pubTimestamp":1776639291,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nTUEBXGNC7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627942502","title":"Radiopharm Theranostics Completes Enrollment in U.S. Phase 2B Imaging Trial of Rad 101 for Diagnosis of Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2627942502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627942502?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:00","pubTimestamp":1776337201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA5YJYBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627257450","title":"Radiopharm Theranostics Completes Dosing of Final Patient in Phase 2B Imaging Trial in Recurrent Brain Metastases from Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257450","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627257450?lang=en_us&edition=fundamental","pubTime":"2026-04-16 10:17","pubTimestamp":1776305846,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  completed the dosing of the final patient in the US phase 2b imaging trial evaluating the diagnostic performance of fluorine-18-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins, according to a Thursday Australian bourse filing.The primary objective of the study is concordance between fluorine-18-RAD101 positive lesions and those seen in conventional imaging, magnetic resonance imaging with gadolinium, in participants with suspected recurrent brain metastases.RAD 101 is a novel imaging small molecule that targets fatty acid synthase , a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625946766","title":"BRIEF-Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625946766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625946766?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:14","pubTimestamp":1775650496,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical TrialApril 8 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:RADIOPHARM THERANOSTICS ADVANCES TO COHO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R18I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625948007","title":"Radiopharm Theranostics Advances to Cohort 3 in 177Lu-Rad202 Phase 1 Dose Escalating Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625948007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625948007?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:01","pubTimestamp":1775646063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R18I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625438599","title":"Radiopharm Theranostics Ltd: on Track to Complete Phase 1 Dose Escalation by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625438599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625438599?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:01","pubTimestamp":1775646063,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R18I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625990372","title":"Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625990372","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625990372?lang=en_us&edition=fundamental","pubTime":"2026-04-08 14:19","pubTimestamp":1775629155,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie  from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 -positive advanced solid tumors, according to a Wednesday Australian bourse filing.The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.Its shares rose 5% in recent trading on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932378","title":"Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for Rad101 in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932378?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA64DWPJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625986839","title":"BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101","url":"https://stock-news.laohu8.com/highlight/detail?id=2625986839","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625986839?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:28","pubTimestamp":1775528920,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101April 7  - Radiopharm Theranostics Ltd RAD.AX:RAD AND SIEMENS SIGN CLINICAL SUPPLY AGREEMENT FOR RAD101SIEMENS HEALTHINEERS WILL RADIOLABEL, DISTRIBUTE RAD101 WITH FLUORINE-18 Further company coverage: RAD.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625607639","title":"Radiopharm Theranostics Ltd -  Rad and Siemens Sign Clinical Supply Agreement for Rad101","url":"https://stock-news.laohu8.com/highlight/detail?id=2625607639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625607639?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:31","pubTimestamp":1775514700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624261595","title":"Radiopharm Theranostics director Noel Donnelly files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624261595","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624261595?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:46","pubTimestamp":1775094416,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Noel Donnelly reported options to buy 8 million ordinary shares exercisable at AUD 0.06, with expirations through Sept. 30, 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL1w6z3s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551776","title":"Radiopharm Theranostics files Form 3 for director Denise Hester Larkin","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551776","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624551776?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:31","pubTimestamp":1774999904,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Denise Hester Larkin filed an initial Form 3 showing 644,247 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLc5HNrQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":67,"code":"91000000","status":"200"}]}}